Dr. Shah on Initial Results for bb21217 in Multiple Myeloma

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses initial results from a phase I clinical trial of bb21217, a next-generation anti-BCMA CAR T-cell therapy, in patients with multiple myeloma during the 2018 ASH Annual Meeting.

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses initial results from a phase I clinical trial of bb21217, a next-generation anti-BCMA CAR T-cell therapy, in patients with multiple myeloma during the 2018 ASH Annual Meeting.

<<< 2018 ASH Annual Meeting

Related Content:

ASH Annual Meeting and ExpositionConferenceMultiple MyelomaHematologic Oncology
OncLive’s June Roundup of Key FDA Approvals in Oncology
Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer
Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer